Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.54

-3.1%

Nov 18 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote ()	4/21/2000 1:53:00 AM
From: paradigm7241	Read Replies (1) of 52153

Amgen versus TKTX on Epo: I would like to get everyone's opinion on the battle between TKT and Amgen with regard to the production of human Epo. Amgen is in litigation with TKT, arguing that TKT's production of native human Epo infringes on their patent whereby the production of human recombinant Epo in any vertebrate cell is protected. TKT forces the overexpression of endogenous human Epo by introducing a constitutively active promoter region upstream of the Epo gene in a human cell line which does not normally produce Epo. Amgen introduced an Epo transgene into CHO cells. No Epo transgene is used by TKT. I have set up a Transkaryotic Therapies (TKTX) thread to discuss TKTX and this issue. Please post your thoughts.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next